Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Sun Pharmaceutical Industries announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Gross sales at Rs 132,642 million, growth of 10.5%. India formulation sales at Rs 42,652 million, up 11%. US formulation sales at USD 517 million, up 20.3%. Global Specialty sales at USD 286 million, up 19.2%. Emerging Markets formulation sales at USD 293 million, up 3.2%. Rest of World formulation sales at USD 199 million, down 3.5%. R&D; investments at Rs 7,929 million compared to Rs 7,734 million for Q2FY24. EBITDA at Rs 39,390 million (including other operating revenues), up 23.9%, with resulting EBITDA margin of 29.6%. Net profit for Q2FY25 was Rs 30,402 million, up 28% YoY. H1FY25 Financial Highlights: Gross sales at Rs 257,887 million, growth of 8.4%. India formulation sales at Rs 84,097 million, up 13.6%. US formulation sales at USD 983 million, up 9.1%. Emerging Markets formulation sales at USD 577 million, up 5.9%. Rest of World formulation sales at USD 388 million, down 3.2%. EBITDA at Rs 75,466 million (including other operating revenues), up 15.9%, with resulting EBITDA margin of 29.1%. Net profit for H1FY25 was at Rs 58,758 million, up 24.5% over the adjusted Net Profit of H1FY24. Dilip Shanghvi, Chairman and Managing Director of the Company said: “Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercializing late stage candidate Fibromun, upon approval. With Fibromun, our product basket for dermatologists has expanded further. We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market.” Result PDF